KRL 901

Drug Profile

KRL 901

Alternative Names: KRL-901

Latest Information Update: 26 Mar 2009

Price : $50

At a glance

  • Originator Krele Pharmaceuticals
  • Developer Krele Pharmaceuticals Inc
  • Class Drug withdrawal therapies
  • Mechanism of Action Aldehyde dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Clinical Phase Unknown Alcoholism

Most Recent Events

  • 26 Mar 2009 Clinical trials in Alcoholism in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top